TP53 and cancer: Mutant-p53 binds to p73 to form an inhibited complex, consequently sequestering p73 and blocking transactivation of target genes and downstream biological functions26 hence disrupting interaction of mutant-p53 and p73 leading to p73 release is a promising strategy to restore p53-pathway in cancer therapy.